Dara-KRd + Tandem autoSCT for high-risk Transplant-Eligible Multiple Myeloma
IFM 2018-04
Background : Multiple myeloma is a cancer of plasma cells. About 15% of multiple myeloma harbors high-risk cytogenetic features. It is important to study the efficacy of treatment in this patient population as they are at high-risk of shorter remissions, disease relapses, refractory disease and ultimately death from multiple myeloma.
The IFM 2018-04 st…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.